Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation

Conclusion: Given the durable response observed, olaparib can be a valuable therapeutic tool in BRCA-mutant CCAs. Ongoing and future clinical trials are needed to confirm the role of PARP inhibition in similar patients and to define the clinicopathologic and molecular profile of the individuals most likely to benefit.
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research